

Centre for Heart Lung Innovation Research in Progress (R.I.P.)



Development of oncolytic coxsackievirus B3 for lung cancer therapy

Huitao Liu PhD student Dr. Honglin Luo

Monday, Sept 13th, 2021 9:00 - 10:00 a.m.

Zoom Video Conference (Meeting ID: 693 1997 7044; Passcode: 030679)

"miRNA modification is a powerful strategy to enhance the safety of oncolytic viruses. We previously discovered that miRNA-modified coxsackievirus B3 (CVB3) could be a potent oncolytic candidate for several lung cancer subtypes. Nevertheless, I found that the modified viral genome is not stable. To improve the stability of miRNA modification, I generated two recombinant CVB3s by inserting a short miRNA-target sequence into 5'UTR and coding region of viral genome, respectively. In the RIP, I will present and discussion my recent data examining the stability, safety and efficacy of these two miRNA-modified viruses in treating lung cancer both in vitro and in vivo."

This event is a Self-Approved Group Learning Activity as defined by the Maintenance Certification Program of the Royal College of Physicians and Surgeons of Canada





